{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:07:01Z","timestamp":1792598821984,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>\n                      This study aims to evaluate the correlation between Tumor-Infiltrating Lymphocyte (TIL) levels and Fluorine-18 fluorodeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG) metabolic parameters, including spleen and bone marrow FDG uptake and tumor heterogeneity in non-luminal breast cancers (NLBC), and to elucidate their association with survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed data from 100 females with stage 2\u20134 NLBC who underwent pretreatment\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG Positron emission tomography-computed tomography (PET\/CT). TIL was scored based on Hematoxylin-Eosin-stained specimens and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET metabolic parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), liver, spleen, and bone marrow FDG uptake were calculated. Heterogeneity Index (HI)1, HI2, and HI3 indices were analyzed with FDG metabolic parameters. The association between these factors and overall survival was analyzed using multivariate Cox regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TIL showed weak negative correlations with tumor size, tumor (T), and metastasis (M) stages. No significant correlation was found between TIL levels and overall SUV values. However, in stage 4, TIL correlated positively with liver, spleen, and bone marrow SUV values and negatively with heterogeneity indices (HI2, HI3). Higher tumor size, HI values, and Bone marrow-to-liver ratio (BLR) SUVmean were associated with increased mortality. A TIL cut-off value of &amp;lt;5 was linked to significantly worse survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates a strong connection between TIL, FDG metabolic parameters, and tumor heterogeneity, particularly in advanced NLBC. Although TIL is not generally associated with SUV values, its association with certain metabolic and heterogeneity indices suggests that it is important in influencing survival. Further research involving larger cohorts and diverse breast cancer subtypes is needed to validate these results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/pore.2024.1612014","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:11:44Z","timestamp":1736291504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the correlation between pretreatment 18F-FDG PET\/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival"],"prefix":"10.3389","volume":"30","author":[{"given":"Muge","family":"Tamam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halim","family":"Ozcevik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Kulduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Nur","family":"Acar Tayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunduzalp Bugrahan","family":"Babacan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes \u2013 dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILS) in breast cancer: recommendations by an International TILS Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s12094-015-1391-y","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/his.13695","article-title":"Heterogeneity of tumor-infiltrating lymphocytes in breast cancer and its prognostic significance","volume":"73","author":"Althobiti","year":"2018","journal-title":"Histopathology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.31557\/APJCP.2022.23.2.553","article-title":"Prognostic value of tumor infiltrating lymphocytes in locally advanced HER2 enriched breast cancer","volume":"23","author":"Saber","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108773","DOI":"10.1016\/j.ejrad.2019.108773","article-title":"Correlation between 18F-FDG uptake on PET\/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer","volume":"123","author":"Murakami","year":"2020","journal-title":"Eur J Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03661-8","article-title":"Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis","author":"de Moraes","year":"","journal-title":"Clin Transl Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110661","DOI":"10.1016\/j.ejrad.2022.110661","article-title":"Relationship between FDG-PET and the immune microenvironment in breast cancer","volume":"158","author":"Kitajima","year":"2023","journal-title":"Eur J Radiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1007\/s00259-021-05322-2","article-title":"Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET\/CT as independent prognostic biomarkers of recurrence in resected breast cancer","volume":"48","author":"Seban","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B12","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.1038\/s41598-021-91404-y","article-title":"Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring 1 cm","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13550-020-00660-y","article-title":"[18F]FDG uptake of bone marrow on PET\/CT for predicting distant recurrence in breast cancer patients after surgical resection","volume":"10","author":"Lee","year":"2020","journal-title":"EJNMMI Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/bjr\/tqad015","article-title":"Elevated splenic 18F-fluorodeoxyglucose positron emission tomography\/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast","volume":"97","author":"Wang","year":"2024","journal-title":"Br J Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0208861","DOI":"10.1371\/journal.pone.0208861","article-title":"Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET\/CT for prediction of tumor recurrence in breast cancer","volume":"13","author":"Bang","year":"2018","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10238-020-00659-8","article-title":"Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes","volume":"21","author":"Liu","year":"2021","journal-title":"Clin Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2214\/AJR.11.7336","article-title":"Nasopharyngeal carcinoma: investigation of intratumoral heterogeneity with FDG PET\/CT","volume":"199","author":"Huang","year":"2012","journal-title":"Am J Roentgenol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1007\/s00259-023-06333-x","article-title":"Can tumor heterogeneity in TNBC obtained with FDG PET\/CT predict survival? Novel method: heterogeneity index 3","volume":"50","author":"Babacan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.21873\/anticanres.14323","article-title":"Tumor-infiltrating lymphocyte score based on FDG PET\/CT for predicting the effect of neoadjuvant chemotherapy in breast cancer","volume":"40","author":"Sasada","year":"2020","journal-title":"Anticancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","article-title":"Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12032-023-02036-3","article-title":"Tumor infiltrating lymphocytes and radiological picture of the tumor","volume":"40","author":"Frankowska","year":"2023","journal-title":"Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10549-019-05339-0","article-title":"The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer","volume":"177","author":"Sasada","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s10549-020-05619-0","article-title":"FDG uptake reflects breast cancer immunological features:the PD-L1 expression and degree of TILs in primary breast cancer","volume":"181","author":"Hirakata","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12253-019-00641-0","article-title":"Dynamic FDG-PET\/CT in the initial staging of primary breast cancer: clinicopathological correlations","volume":"26","author":"Kaj\u00e1ry","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00259-017-3755-8","article-title":"Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET\/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma","volume":"44","author":"Kim","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1097\/MNM.0000000000001058","article-title":"The association between 18F-fluorodeoxyglucose PET intratumoral metabolic heterogeneity and pathological parameters in non-small cell lung cancer","volume":"40","author":"Li","year":"2019","journal-title":"Nucl Med Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jso.24275","article-title":"No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: validation of recommendations by the International TILs Working Group 2014","volume":"114","author":"Park","year":"2016","journal-title":"J Surg Oncol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1612014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:11:47Z","timestamp":1736291507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2024.1612014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":28,"alternative-id":["10.3389\/pore.2024.1612014"],"URL":"https:\/\/doi.org\/10.3389\/pore.2024.1612014","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"article-number":"1612014"}}